减少剂量蒂卡格勒罗,全剂量蒂卡格勒罗和克洛皮多格雷尔在急性中风管理中的比较有效性
Harsh Desai1, Varun Viswanath2, Elena Badillo Goicoechea1
1Department of Neurology, University of Chicago, Chicago, IL, USA.
概括
在急性缺血性中风或短暂缺血性发作后使用蒂卡格勒与克洛皮多格雷尔相比,与90天死亡率的降低有关. 降低剂量的提卡格勒勒显示效果与全剂量相似,这表明可能需要进一步研究.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 提卡格勒越来越多地用于急性缺血性中风和短暂缺血性发作.
- 在这种患者群体中,提卡格勒的最佳剂量策略尚不清楚.
- 与克洛皮多格雷尔的比较对于指导治疗决策至关重要.
研究的目的:
- 为了比较降低剂量提卡格勒罗 (45/60毫克两次一天),全剂量提卡格勒罗 (90毫克两次一天) 和克洛皮多格雷尔 (75毫克每天) 的有效性和安全性.
- 为了评估这些抗血小板药物治疗的患者中继性中风预防的结果.
主要方法:
- 对562名急性缺血性中风或短暂缺血性发作患者进行了回顾性队列研究.
- 主要结局:90天死亡率和90天功能独立性 (修改的兰金尺度0-2).
- 使用逆概率权重进行治疗组比较的倾向性得分调整.
主要成果:
- 与克洛皮多格雷尔相比,提卡格雷勒的使用与90天死亡率显著降低 (OR0.51,p=0.03).
- 在蒂卡格雷勒和克洛皮多格雷尔 (OR 0.64,p=0.18) 之间没有发现90天功能独立的显著差异.
- 降低剂量提卡格勒罗的90天死亡率和功能独立性与全剂量提卡格勒罗相比相当.
结论:
- 提卡格勒勒的使用与急性缺血性中风或短暂缺血性发作后90天死亡率的降低有关.
- 降低剂量的提卡格勒与全剂量的提卡格勒一样有效.
- 降低剂量的提卡格勒需要在二次中风预防的前性研究中进一步调查.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
01:28Acute Coronary Syndrome IV: Interprofessional Care
203
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
203
01:30Acute Coronary Syndrome III: Diagnostic Studies
200
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
200
01:29Venous Thrombosis III: Interprofessional Care
268
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
268
01:30Acute Coronary Syndrome I: Introduction
744
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
744